Topamax® (topiramate): Updated Warnings and Precautions on Visual Field Defects


User Rating: 1 / 5

Star ActiveStar InactiveStar InactiveStar InactiveStar Inactive

Date: 17 October 2014

Description: The NPCB has approved a Direct Healthcare Professional Communication (DHPC) to alert healthcare professionals that visual field defects have been reported in patients receiving topiramate, independent of elevated intraocular pressure. Healthcare professionals should consider discontinuing the drug if visual problems occur at any time during treatment. The package inserts for Topamax® have been updated by Janssen, a division of Johnson & Johnson Sdn. Bhd. to reflect this new safety information. Please refer to the DHPC for further information.